{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T18:35:39Z","timestamp":1793730939265,"version":"4.6.1"},"reference-count":83,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T00:00:00Z","timestamp":1690329600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Lipoprotein(a), or Lp(a), is structurally like low\u2010density lipoprotein (LDL) but differs in that it contains glycoprotein apolipoprotein(a) [apo(a)]. Due to its prothrombotic and proinflammatory properties, Lp(a) is an independent risk factor for atherosclerotic cardiovascular disease (ASCVD) and aortic valve stenosis. Lp(a) levels are genetically determined, and it is estimated that 20%\u201325% of the global population has an Lp(a) level \u226550\u2009mg\/dL (or \u2265125\u2009nmol\/L). Diet and lifestyle interventions have little to no effect on Lp(a) levels. Lipoprotein apheresis is the only approved treatment for elevated Lp(a) but is time\u2010intensive for the patient and only modestly effective. Pharmacological approaches to reduce Lp(a) levels and its associated risks are of significant interest; however, currently available lipid\u2010lowering therapies have limited effectiveness in reducing Lp(a) levels. Although statins are first\u2010line agents to reduce LDL cholesterol levels, they modestly increase Lp(a) levels and have not been shown to change Lp(a)\u2010mediated ASCVD risk. Alirocumab, evolocumab, and inclisiran reduce Lp(a) levels by 20\u201025%, yet the clinical implications of this reduction for Lp(a)\u2010mediated ASCVD risk are uncertain. Niacin also lowers Lp(a) levels; however, its effectiveness in mitigating Lp(a)\u2010mediated ASCVD risk remains unclear, and its side effects have limited its utilization. Recommendations for when to screen and how to manage individuals with elevated Lp(a) vary widely between national and international guidelines and scientific statements. Three investigational compounds targeting Lp(a), including small interfering RNA (siRNA) agents (olpasiran, SLN360) and an antisense oligonucleotide (pelacarsen), are in various stages of development. These compounds block the translation of messenger RNA (mRNA) into apo(a), a key structural component of Lp(a), thereby substantially reducing Lp(a) synthesis in the liver. The purpose of this review is to describe current recommendations for screening and managing elevated Lp(a), describe the effects of currently available lipid\u2010lowering therapies on Lp(a) levels, and provide insight into emerging therapies targeting Lp(a).<\/jats:p>","DOI":"10.1002\/phar.2851","type":"journal-article","created":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T01:36:20Z","timestamp":1689730580000},"page":"1051-1063","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":54,"title":["Role of lipoprotein(a) in atherosclerotic cardiovascular disease: A review of current and emerging therapies"],"prefix":"10.1002","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-3346-1223","authenticated-orcid":false,"given":"Ibrahim S.","family":"Alhomoud","sequence":"first","affiliation":[{"name":"Department of Pharmacotherapy &amp; Outcomes Science Virginia Commonwealth University Richmond Virginia USA"},{"name":"Department of Pharmacy Practice, College of Pharmacy Qassim University Buraidah Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1839-3685","authenticated-orcid":false,"given":"Azita","family":"Talasaz","sequence":"additional","affiliation":[{"name":"Department of Pharmacotherapy &amp; Outcomes Science Virginia Commonwealth University Richmond Virginia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6910-5551","authenticated-orcid":false,"given":"Anurag","family":"Mehta","sequence":"additional","affiliation":[{"name":"Division of Cardiology Virginia Commonwealth University Richmond Virginia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4272-8721","authenticated-orcid":false,"given":"Michael S.","family":"Kelly","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice Thomas Jefferson University College of Pharmacy Philadelphia Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3961-853X","authenticated-orcid":false,"given":"Evan M.","family":"Sisson","sequence":"additional","affiliation":[{"name":"Department of Pharmacotherapy &amp; Outcomes Science Virginia Commonwealth University Richmond Virginia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3396-2612","authenticated-orcid":false,"given":"John D.","family":"Bucheit","sequence":"additional","affiliation":[{"name":"Department of Pharmacotherapy &amp; Outcomes Science Virginia Commonwealth University Richmond Virginia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0627-9132","authenticated-orcid":false,"given":"Roy","family":"Brown","sequence":"additional","affiliation":[{"name":"School of Nursing Virginia Commonwealth University Richmond Virginia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7560-9521","authenticated-orcid":false,"given":"Dave L.","family":"Dixon","sequence":"additional","affiliation":[{"name":"Department of Pharmacotherapy &amp; Outcomes Science Virginia Commonwealth University Richmond Virginia USA"},{"name":"Division of Cardiology Virginia Commonwealth University Richmond Virginia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,7,26]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1699-0463.1963.tb01808.x"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.801"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.1063"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.09.042"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.107.715698"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.R067314"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11883-021-00940-5"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2022.0987"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2011.07.005"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2022.04.008"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.5551\/jat.RV17034"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2016.09.012"},{"issue":"25","key":"e_1_2_5_14_1","first-page":"e1082","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/ APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"139","author":"Grundy SM","year":"2019","journal-title":"Circulation"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehq386"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.116.308011"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.5333"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.120.315291"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.09.038"},{"issue":"1","key":"e_1_2_5_20_1","first-page":"16","article-title":"Lipoprotein apheresis: first FDA indicated treatment for elevated lipoprotein(a)","volume":"1","author":"Nugent AK","year":"2020","journal-title":"J Clin Cardiol"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.3390\/nu12072024"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.11.002"},{"key":"e_1_2_5_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz455"},{"key":"e_1_2_5_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2021.03.016"},{"key":"e_1_2_5_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2019.04.010"},{"key":"e_1_2_5_26_1","doi-asserted-by":"publisher","DOI":"10.1161\/ATV.0000000000000147"},{"key":"e_1_2_5_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac361"},{"issue":"1","key":"e_1_2_5_28_1","first-page":"41","article-title":"Developing optimal search strategies for detecting clinically sound treatment studies in EMBASE","volume":"94","author":"Wong SSL","year":"2006","journal-title":"J Med Libr Assoc"},{"key":"e_1_2_5_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-1842.2008.00827.x"},{"key":"e_1_2_5_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1806939"},{"key":"e_1_2_5_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurjpc\/zwab171"},{"key":"e_1_2_5_32_1","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.R053066"},{"key":"e_1_2_5_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2021.01.051"},{"key":"e_1_2_5_34_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz310"},{"key":"e_1_2_5_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacbts.2016.06.006"},{"key":"e_1_2_5_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-0870-1"},{"key":"e_1_2_5_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2007.12.065"},{"key":"e_1_2_5_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0195-668x(02)00803-5"},{"key":"e_1_2_5_39_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000068312.21969.C8"},{"key":"e_1_2_5_40_1","doi-asserted-by":"publisher","DOI":"10.4065\/79.5.620"},{"key":"e_1_2_5_41_1","doi-asserted-by":"publisher","DOI":"10.1185\/030079905X28872"},{"key":"e_1_2_5_42_1","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.003323"},{"key":"e_1_2_5_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2016.09.010"},{"key":"e_1_2_5_44_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615664"},{"key":"e_1_2_5_45_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801174"},{"key":"e_1_2_5_46_1","doi-asserted-by":"publisher","DOI":"10.1177\/2047487320915803"},{"key":"e_1_2_5_47_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.118.037184"},{"key":"e_1_2_5_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2014.05.060"},{"key":"e_1_2_5_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2014.01.006"},{"key":"e_1_2_5_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.10.057"},{"key":"e_1_2_5_51_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/suaa135"},{"key":"e_1_2_5_52_1","unstructured":"A Randomized Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Cardiovascular Disease (ORION\u20104). ClinicalTrials.gov Identifier: NCT03705234. Accessed May 15 2023.http:\/\/clinicaltrials.gov\/ct2\/show\/NCT03705234"},{"key":"e_1_2_5_53_1","unstructured":"Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease (VICTORION\u20102P).ClinicalTrials.govIdentifier: NCT05030428. Accessed May 15 2023.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05030428"},{"key":"e_1_2_5_54_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1912387"},{"key":"e_1_2_5_55_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2215024"},{"key":"e_1_2_5_56_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.16585"},{"key":"e_1_2_5_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2018.06.002"},{"key":"e_1_2_5_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2021.05.002"},{"key":"e_1_2_5_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2023.02.002"},{"key":"e_1_2_5_60_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1107579"},{"key":"e_1_2_5_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2016.08.007"},{"key":"e_1_2_5_62_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1300955"},{"key":"e_1_2_5_63_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1994.03510370051031"},{"key":"e_1_2_5_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9150(82)90053-3"},{"key":"e_1_2_5_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2009.12.007"},{"key":"e_1_2_5_66_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-020-0991-1"},{"key":"e_1_2_5_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2010.08.068"},{"key":"e_1_2_5_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2008.01.026"},{"key":"e_1_2_5_69_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2210645"},{"key":"e_1_2_5_70_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.122.059410"},{"key":"e_1_2_5_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61731-0"},{"key":"e_1_2_5_72_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2004215"},{"key":"e_1_2_5_73_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2018.1470"},{"key":"e_1_2_5_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2018.03.004"},{"key":"e_1_2_5_75_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1905239"},{"key":"e_1_2_5_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)61252-1"},{"key":"e_1_2_5_77_1","unstructured":"Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD (Lp[a]HORIZON).ClinicalTrials.govIdentifier: NCT04023552. Accessed May 15 2023.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04023552"},{"key":"e_1_2_5_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2022.07.008"},{"key":"e_1_2_5_79_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2211023"},{"key":"e_1_2_5_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2022.05.004"},{"key":"e_1_2_5_81_1","unstructured":"Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN[a]) \u2010 Outcomes Trial.ClinicalTrials.govIdentifier: NCT05581303. Accessed May 15 2023.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05581303"},{"key":"e_1_2_5_82_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2022.03.029"},{"key":"e_1_2_5_83_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.5050"},{"key":"e_1_2_5_84_1","unstructured":"Evaluate SLN360 in Participants With Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease Events.ClinicalTrials.govidentifier: NCT05537571. Accessed May 15 2023.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05537571"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.2851","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:37:21Z","timestamp":1761061041000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/phar.2851"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,26]]},"references-count":83,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["10.1002\/phar.2851"],"URL":"https:\/\/doi.org\/10.1002\/phar.2851","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,26]]},"assertion":[{"value":"2023-03-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}